COVID-19 Update

July 2021

A message to our customers and partners:

Vector Laboratories is continuously monitoring and assessing the current situation with respect to the coronavirus (COVID-19) outbreak and responding appropriately as it evolves.

As COVID-19 continues to impact our communities, we are mindful that there may be concerns regarding ordering and general delays. Our commitment is to remain in operation in order to supply mission critical products to our customers and partners. We have an active Business Continuity Plan in place and specific response plan to the COVID-19 situation.

Currently, our efforts are enabling critical research by providing high-quality and efficient delivery of reagents for immunohistochemistry, immunofluorescence, bioconjugation, and glycobiology. We provide critical reagents that are making an immediate impact in global health and safety, and we are doing everything in our power to maintain business as usual.

As of today, we are currently experiencing no business interruption and our facility remains open and operational.

Impact to Manufacturing:

Our manufacturing and support teams continue to be operational. We are maintaining tight communication and are working closely with our suppliers to ensure uninterrupted manufacturing workflows. We have conducted a risk assessment of our supply chain, resources and facilities and they are secure at this time. Within our manufacturing facility, we are following the guidelines of local and national health organizations in order to mitigate the spread of COVID-19.

Impact to Business Operations:

Vector Laboratories is taking all recommended precautions to ensure that we keep our employees and their families safe, while maintaining our business continuity in support of our customers. Our customer service and order fulfillment teams continue to operate to ensure that all customer orders are processed promptly and that we continue to meet our customers’ expectations. Workplace recommendations by WHO, CDC, and local and national authorities are being implemented, including:

  • Allowing all essential employees not needed to be on-site to work from home
  • Allowing our sales and technical support teams work remotely to continue to provide expert consultative and technical support through our existing phone lines or via email
  • Hosting virtual alternatives to meetings and conferences
  • Heightening hygiene protocols
  • Prohibiting guests from entering our facility

If you have any questions or concerns, please email us at [email protected] or [email protected]. We are also available by phone at +1 (800) 227-6666 or +1(650) 697-3600.